following a full submission assessed under the end of life and orphan equivalent process:
avelumab (Bavencio®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy.
In a phase III study, maintenance treatment with avelumab plus best supportive care (BSC) significantly improved overall survival when compared with BSC alone.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- avelumab (Bavencio)
- SMC ID:
As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy
- Pharmaceutical company
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 09 August 2021